Introduction

Established in 2002, Hangzhou FST Pharmaceutical focuses on advanced intermediates, APIs, and nutraceuticals. In 2022, it was acquired by Shanghai Eyougene Biotechnology, founded by top Fudan University graduates. Eyougene excels in digital CDMO services for advanced intermediates and new materials.  The group has R&D centers in Shanghai, Xi'an, and Wuhan, with 382 employees, including 169 R&D and QA professionals. The main products include cardiovascular, gastrointestinal, and weight control products. 
 Located in Jiande Hangzhou, the factory complies with GMP and holds ISO9001:2000, ISO14001, and OHSAS18001 certifications. Eyougene is committed to life science innovation for human health.
Here is the profile of Eyougene and FST.  You can find the introduction of company, technology, products,production system and business partners.